This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Methysergide maleate
Description: Sansert has been shown to block inhibit or block theeffects of serotonin, a substance which may be involved in the mechanism of vascularheadaches. Serotonin has been variously described as a central neurohumoral agent orchemical mediator, as a “headache substance” acting directly or indirectly to lower painthreshold, as an intrinsic “motor hormone” of the gastrointestinal tract,and as a “hormone” involved in connective tissue reparative processes.
Pink Sheet Novartis Sansert discontinued
Additional information available to subscribers only: